Friday, December 17, 2021

Pfizer-BionTech 3 doses to fight Omicron press release reversed a week long, significant fall in BioNTech share price

 by Ganesh Sahathevan 



The Pfizer-BioNTech press release of 8 December 2021 seems to have rescued BioNTech's  share price. 





Pfizer and BioNTech Provide Update on Omicron Variant

  • Preliminary laboratory studies demonstrate that three doses of the Pfizer-BioNTech COVID-19 Vaccine neutralize the Omicron variant (B.1.1.529 lineage) while two doses show significantly reduced neutralization titers
  • Data indicate that a third dose of BNT162b2 increases the neutralizing antibody titers by 25-fold compared to two doses against the Omicron variant; titers after the booster dose are comparable to titers observed after two doses against the wild-type virus which are associated with high levels of protection
  • As 80% of epitopes in the spike protein recognized by CD8+ T cells are not affected by the mutations in the Omicron variant, two doses may still induce protection against severe disease
  • The companies continue to advance the development of a variant-specific vaccine for Omicron and expect to have it available by March in the event that an adaption is needed to further increase the level and duration of protection – with no change expected to the companies’ four billion dose capacity for 2022




No comments:

Post a Comment